Bowen Acquisition Corp Reports $1.56 Million Net Loss for Fiscal Year 2025

Bowen Acquisition Corp, a blank check company incorporated in February 2023, reported a net loss of $1.56 million for the fiscal year ending December 31, 2025. This loss was primarily attributed to operating costs of $351,661 and total other expenses of $1.56 million, which included interest expenses and losses related to a Forward Purchase Agreement. In contrast, the previous fiscal year (2024) saw a net income of $2.96 million, driven by interest income from the Trust Account, which amounted to $3.68 million. The company has not generated any operating revenue to date, as its activities have focused on identifying a target for its initial business combination.

Bowen Acquisition Corp successfully completed its initial public offering (IPO) on July 14, 2023, raising gross proceeds of $60 million from the sale of 6 million units at $10 each. Additionally, a private placement of 330,000 units generated $3.3 million. Following the IPO, the underwriters exercised their over-allotment option, resulting in an additional $9 million in proceeds. As of December 31, 2025, the company had approximately $7.67 million held in its Trust Account, which is intended to be used for the completion of its initial business combination.

In a significant strategic development, Bowen entered into a Business Combination Agreement on January 18, 2024, with Shenzhen Qianzhi BioTechnology Co. Ltd. and its parent company, Qianzhi Group Holding (Cayman) Limited. This agreement outlines a merger that will see Qianzhi become a wholly owned subsidiary of Bowen. The transaction is expected to involve the issuance of approximately 7.25 million ordinary shares of Bowen to the shareholders of NewCo, contingent upon the successful completion of the merger and the achievement of certain net income milestones.

Operationally, Bowen has faced challenges, including a working capital deficit of $2.37 million as of the end of 2025. The company has also experienced redemptions of public shares, with over 6 million shares redeemed at prices ranging from approximately $10.99 to $11.38 during various extraordinary general meetings held in 2025. These redemptions indicate a cautious sentiment among investors regarding the company's ability to complete its business combination within the stipulated timeframes. The company has sought extensions to its deadline for completing the merger, with the latest extension allowing until June 14, 2026.

Looking ahead, Bowen Acquisition Corp is focused on finalizing its business combination with Qianzhi. However, the company has acknowledged substantial doubt about its ability to continue as a going concern if it cannot complete the merger or secure alternative financing. The management has outlined plans to address these concerns, including potential loans and seeking alternative ways to maintain its public trading status. The outcome of these efforts will be critical in determining the future trajectory of Bowen Acquisition Corp and its intended business operations.